Homogenous antibody drug conjugates via enzymatic methods
AssigneeCSPC Dophen Corporation
InventorsSean HU, Lisha ALLEN
Life of this patent
Estimating the term…
Loading patent…
AssigneeCSPC Dophen Corporation
InventorsSean HU, Lisha ALLEN
Estimating the term…
The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
1-20. (canceled)
A method of treating cancer in an individual, comprising administering to the individual an effective amount of an antibody drug conjugate comprising an antibody conjugated to a conjugation moiety via an endogenous acceptor glutamine residue on the antibody, wherein the antibody drug conjugate is glycosylated in the Fc region, wherein the conjugation moiety comprises a cleavable linker, and wherein the conjugation moiety is:
Dependencies are inferred from the claim text.